Business Context and Reporting Period
This Form 8-K Current Report was filed by Immunocore Holdings Plc on May 28, 2024. The filing discloses the entry into a material definitive agreement and the appointment of a new director to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or liquidity metrics. The only financial data disclosed relates to specific transaction terms:
- Convertible Notes: In February 2024, the BBA Funds purchased $60,000,000 in aggregate principal amount of 2.50% Convertible Senior Notes due 2030.
- Director Compensation: The newly appointed director, Mr. Ranjeev Krishana, received an option grant to purchase an estimated $325,790 of the Company's ordinary shares.
Material Changes
The filing reports the following material changes effective May 28, 2024:
- Board Appointment: Mr. Ranjeev Krishana was appointed as a Class I director, nominated by the BBA Funds (667, L.P. and Baker Brothers Life Sciences, L.P.). His term expires at the 2025 annual meeting of shareholders.
- Registration Rights Agreement: The Company entered into a new Registration Rights Agreement with the BBA Funds. This agreement grants the BBA Funds resale registration rights for their Registrable Securities (Ordinary Shares, Non-Voting Ordinary Shares, and ADSs).
- Underwriting Rights: The BBA Funds secured the right to one underwritten offering per calendar year (up to three total) and up to two underwritten offerings or block trades in any 12-month period.
Outlook, Risks, and Management Commentary
Management Commentary: The appointment of Mr. Krishana follows a recommendation by the Nominating and Corporate Governance Committee. Mr. Krishana brings experience as a partner at Baker Bros. Advisors LP and prior leadership roles at Pfizer, Inc.
Contingencies and Agreements:
- The Company is obligated to file a resale registration statement on Form S-3 within 60 days of a request by the BBA Funds, subject to specified exceptions.
- The Company must pay certain expenses related to these registrations and indemnify the BBA Funds against certain liabilities.
- A previous registration rights agreement with the BBA Funds terminated automatically on April 30, 2024, superseded by this new agreement.
Risks: The filing does not explicitly list new risk factors, though the agreement includes standard suspension and deferral rights for the Company regarding registration statements.
Investor Verification Checklist
- Verify the terms of the new Registration Rights Agreement (Exhibit 10.2) regarding the 60-day filing obligation and underwriting limits.
- Review the Amendment to the Letter Agreement (Exhibit 10.1) to understand the governance relationship with the BBA Funds.
- Confirm the impact of the $60 million Convertible Senior Notes issued in February 2024 on the Company's capital structure and future dilution.
- Check the Company's proxy statement (Schedule 14A filed April 12, 2024) for details on the non-employee director compensation policy.